
Zoledronic acid given upfront maintains BMD in postmenopausal breast cancer patients
How to Cite
OrthoEvidence. Zoledronic acid given upfront maintains BMD in postmenopausal breast cancer patients. ACE Report. 2013;2(8):33. Available from: https://myorthoevidene.com/AceReport/Report/4488
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole
Cancer. 2012 Mar 1;118(5):1192-201. doi: 10.1002/cncr.26313. Epub 2011 Oct 10Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
OE EXCLUSIVE
Dr. Adam M. Brufsky discusses the use of adjuvant zoledronic acid to maintain bone mass in postmenopausal breast cancer patients.
Synopsis
602 postmenopausal women receiving adjuvant letrozole were randomized either to upfront zoledronic acid or delayed-start zoledronic acid to determine which method minimizes bone-loss. At 5 years follow-up, upfront zoledronic acid was better at maintaining bone mineral density (BMD) in postmenopausal breast cancer patients than the delayed start technique.
To view the full report, start your 30-day free trial today
No credit card required
JOIN LOGIN Forgot Password?Not sure if you want to join OrthoEvidence?
Access this report without an Account.Success, an email containing a link to access this report has been sent to your inbox.
Explore some of our unlocked reports below!

Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.
LEARN MORE
Please Login or Join to leave comments.